Articles From: Baxter to Present at Upcoming Global Healthcare Conferences to Bayer Submits Application for New Use of Eylea Drug


2014/2/10
Baxter International Inc. (NYSE: BAX) announced today that it will present at the Citi 2014 Global Healthcare Conference on Tuesday, February 25, 2014 at 1:40 p.m. (CT) and the 2014 RBC Capital Markets’ Global Healthcare Conference on Wednesday, February 26, 2014 at 8:00 a.m. (CT) The live webcast of Baxter’s presentation along with the slides can be accessed from the Baxter corporate website at www.baxter.com and will be available for replay through March 25, 2014.
Sign-up for Baxter to Present at Upcoming Global Healthcare Conferences investment picks
2013/11/15
By Nathalie Tadena Baxter International Inc. (BAX) and Cell Therapeutics Inc. (CTIC) unveiled an exclusive licensing agreement to develop and commercialize a drug that is used to treat a chronic bone marrow disorder.
Sign-up for Baxter, Cell Therapeutics Sign Licensing Agreement investment picks
2014/4/9
Zix Corporation (ZixCorp), (Nasdaq: ZIXI), a leader in email data protection, announced that Bay Area Medical Center has renewed its contract for Zix TM Email Encryption in a three-year agreement.
Sign-up for Bay Area Medical Center Renews Email Encryption Contract with Zix Corporation investment picks
SAN FRANCISCO, Nov.
Sign-up for Bayad Center Joins Xoom's Payout Network for Money Transfers to the Philippines investment picks
2013/8/26
BERKELEY HEIGHTS, N.J., Aug.
Sign-up for BAYADA Home Health Care Selects Authentidate's Inscrybe to Streamline Care Order Processing and Enable Physician eSignatures investment picks
2013/10/29
FRANKFURT--The following is a summary of analysts' forecasts for Bayer AG (BAYN.XE) third-quarter results, based on a poll of eight analysts conducted by Dow Jones Newswires (figures in million euros, EPS, dividend and target price in euro, according to IFRS). Earnings figures are scheduled to be released October 31.
Sign-up for Bayer AG 3Q 2013 -- Forecast investment picks
FRANKFURT--The following is a summary of analysts' forecasts for Bayer AG (BAYN.XE) fourth-quarter results, based on a poll of nine analysts conducted by Dow Jones Newswires (figures in million euros, EPS, dividend and target price in euro, according to IFRS). Earnings figures are scheduled to be released February 28.
Sign-up for Bayer AG 4Q 2013 -- Forecast investment picks
2014/3/11
WHIPPANY, N.J. , THOUSAND OAKS, Calif.
Sign-up for Bayer and Onyx Report Phase 3 Study Results of NEXAVAR® (sorafenib) as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation investment picks
The supervisory board of Bayer AG (BAYN.XE) appointed Wednesday Kemal Malik to the management board, effective February 1.
Sign-up for Bayer Appoints Kemal Malik to Management Board investment picks
2013/9/30
German chemical and pharmaceutical group Bayer AG (BAYN.XE) Monday said it has appointed Olivier Brandicourt as Chairman of Bayer HealthCare and as a member of Bayer's executive board.
Sign-up for Bayer Appoints Olivier Brandicourt as Bayer HealthCare Chief investment picks
Bayer AG (BAYN.XE) said Tuesday it has completed the issuance of three Eurobonds worth a total of 2 billion euros ($2.71 billion). MAIN FACTS: -The proceeds will be used for general corporate purposes and possible acquisitions.
Sign-up for Bayer Completes Issuance of Bonds Worth EUR2 Billion investment picks
By Neetha Mahadevan Bayer AG (BAYN.XE) said Thursday that it completed the voluntary takeover offer for Norwegian cancer drug maker Algeta ASA (ALGETA.OS) after paying about EUR1.9 billion ($2.61 billion) to Algeta shareholders.
Sign-up for Bayer Completes Voluntary Takeover of Algeta investment picks
Bayer AG (BAYN.XE) confirmed Thursday its full-year outlook after reporting a jump in third-quarter after-tax profit, helped by a drop in extraordinary items and strength in its pharmaceutical and agricultural businesses, but foreign-exchange effects weighed on sales.
Sign-up for Bayer Confirms 2013 Outlook As 3Q Profit Rises investment picks
2013/10/31
By Nicky Redl Bayer AG (BAYN.XE) confirmed Thursday its full-year outlook after reporting a jump in third-quarter after-tax profit, helped by a drop in extraordinary items and strength in its pharmaceutical and agricultural businesses, but foreign-exchange effects weighed on sales.
Sign-up for Bayer Confirms 2013 Outlook As Third-Quarter After-Tax Profit Rises investment picks
Bayer CropScience Joins John Deere in Developing Digital Tools to Move from Precision to Decision™ Canada NewsWire Companies to collaborate on data exchange and analysis RESEARCH TRIANGLE PARK, N.C. , March 13, 2014 /CNW/ - Bayer CropScience and John Deere are working together to integrate data access, wireless data transmission, and delivery of prescription recommendations to help farmers optimize yields and return on investment.
Sign-up for Bayer CropScience Joins John Deere in Developing Digital Tools to Move from Precision to Decision™ investment picks
2014/3/13
Companies to collaborate on data exchange and analysis RESEARCH TRIANGLE PARK, N.C. , March 13, 2014 /PRNewswire/ -- Bayer CropScience and John Deere are working together to integrate data access, wireless data transmission, and delivery of prescription recommendations to help farmers optimize yields and return on investment.
Sign-up for Bayer CropScience Joins John Deere in Developing Digital Tools to Move from Precision to Decision™ investment picks
German chemical company Bayer AG's (BAYN.XE) CropScience segment Thursday says it has entered an agreement to buy soybean producer FN Semillas S.A., marking Bayer's entrance into the Argentinian soybean seed market.
Sign-up for Bayer CropScience To Buy Argentinian Soybean Producer investment picks
FRANKFURT--Bayer AG said it expects strong sales growth for its pharmaceuticals, HeathCare and Crop Protection businesses through 2016.
Sign-up for Bayer Forecasts Strong Sales Growth investment picks
2014/3/31
By Neetha Mahadevan FRANKFURT--Bayer AG (BAYN.XE) said Monday its pulmonary hypertension drug, Adempas, has been approved by the European Commission for the treatment of two chronic forms of hypertension, chalking up another approval for one of its five key drugs.
Sign-up for Bayer Gets EU Approval for Adempas to Treat Lung Disease investment picks
2013/11/15
Bayer AG (BAYN.XE) has been granted marketing authorization for Xofigo for the treatment of adults with prostate cancer, the German drug maker said Friday.
Sign-up for Bayer Gets EU Approval for Prostate Cancer Drug Xofigo investment picks
2013/10/9
German chemcial and pharmaceutical group Bayer AG (BAYN.XE) has received approval from the U.S. Food & Drug Administration to treat lung disease with Adempas, otherwise known as riociguat.
Sign-up for Bayer Gets FDA Approval for Adempas to Treat Lung Disease investment picks
2014/3/3
TARRYTOWN, N.Y. , March 3, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., has submitted an application for marketing authorization for EYLEA ® (aflibercept) Injection for the treatment of patients with diabetic macular edema (DME) to the Japanese Ministry of Health, Labour and Welfare (MHLW). "Clinically significant DME is a leading cause of vision loss in the working-age population suffering from diabetes.
Sign-up for Bayer HealthCare and Regeneron Announce Regulatory Submission of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Japan investment picks
FRANKFURT--German drug maker Bayer AG is in talks to buy Norwegian oncology company Algeta ASA for $2.42 billion, Algeta said Tuesday, as it seeks full control over potential blockbuster cancer treatment Xofigo.
Sign-up for Bayer Moves for Norway's Firm Algeta investment picks
2014/2/26
By Neetha Mahadevan FRANKFURT--Germany's Bayer AG said Wednesday it will increase its 2013 dividend to EUR2.10 ($2.89) a share from EUR1.90 in 2012, ahead of its fourth-quarter results, due Friday.
Sign-up for Bayer Plans Higher Dividend for 2013 investment picks
Bayer AG said Thursday it is offering 17.6 billion Norwegian kroner ($2.87 billion) for Norwegian peer Algeta ASA, more than a preliminary bid, as the German pharmaceutical firm aims to strengthen its portfolio of oncology drugs.
Sign-up for Bayer Raises Algeta Bid to $2.87 Billion investment picks
2013/12/19
By Friedrich Geiger FRANKFURT--Bayer AG (BAYN.XE) said Thursday it is offering 17.6 billion Norwegian kroner ($2.87 billion) for peer Algeta ASA (ALGETA.OS), more than a preliminary bid, as the German pharmaceutical firm aims to strengthen its portfolio of oncology drugs.
Sign-up for Bayer Raises Bid for Algeta to NOK17.6 Billion investment picks
2013/11/28
German chemical and pharmaceutical group Bayer AG (BAYN.XE) said Thursday it has submitted VEGF Trap-Eye to Japan's regulatory authorities for the treatment of myopic choroidal neovascularization, one of the most common causes of blindness.
Sign-up for Bayer Seeks Japan Approval of VEGF Trap-Eye to Treat Blindness investment picks
2013/11/7
German chemicals and pharmaceuticals company Bayer AG (BAYN.XE) said Thursday it has submitted an application for the use of its Eylea drug on patients with diabetic macular edema to authorities in Europe and the U.S. MAIN FACTS: -Bayer submitted the application to the European Medicines Agency and its U.S. sales partner Regeneron submitted the application to the U.S. Food and Drug Administration.
Sign-up for Bayer Submits Application for New Use of Eylea Drug investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Baxter to Present at Upcoming Global Healthcare Conferences to Bayer Submits Application for New Use of Eylea Drug
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity